Drugs
Tamiflu (oseltamivir phosphate) Information
Tamiflu (oseltamivir phosphate) is an oral anti-viral drug approved for the treatment of uncomplicated influenza in patients one year and older whose flu symptoms have not lasted more than two days. This product is approved to treat Type A and B influenza; however, the majority of patients included in the studies were infected with type A, the most common in the U.S. Efficacy of Tamiflu in the treatment of influenza in subjects with chronic cardiac disease and/or respiratory disease has not been established.
Tamiflu is also approved for the prevention of influenza in adults and children aged one year and older. Efficacy of Tamiflu for the prevention of influenza has not been established in immunocompromised patients.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.
Related Information
FDA Drug Safety Communication: Important safety changes to the influenza drug Tamiflu (oseltamivir phosphate) for oral suspension
7/11/2011Comunicado de la FDA sobre la seguridad de los medicamentos: Cambios importantes sobre la seguridad del medicamento para la influenza Tamiflu (fosfato de oseltamivir) para suspensión oral
7/11/2011 FDA Drug Safety Communication in SpanishFDA Drug Safety Podcast for Healthcare Professionals: Important safety changes to the influenza drug Tamiflu (oseltamivir phosphate) for oral suspension
7/11/2011Concentration Lowered in Tamiflu Medication
FDA Consumer UpdateFDA Sounds Alarm on Phony Tamiflu
6/17/2010Tamiflu: Consumer Questions and Answers
11/3/2009- FDA Public Health Alert: Potential Medication Errors with Tamiflu for Oral Suspension (9/25/2009)
Note: Tamiflu Oral Suspension formulation was changed after report of these medication errors. Refer to the 'Prescribing Information' link below for up-to-date product information. Tamiflu (oseltamivir phosphate)
MedWatch Safety Alert (Posted 3/4/2008)Historical Information on Tamiflu (oseltamivir phosphate)
Labeling and Regulatory History from Drugs@FDA
Contact FDA
Regular Mail: Use postage-paid FDA Form 3500
Mail to: MedWatch 5600 Fishers Lane
Rockville, MD 20857
